CL2011001361A1 - Compuestos derivados de n-(imidazo[1,2-a]pirazin-8-il)-1h-amina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades mediadas por inhiibicion de actividad syk, tales como cancer, trastornos alergicos o inflamatorios. - Google Patents

Compuestos derivados de n-(imidazo[1,2-a]pirazin-8-il)-1h-amina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades mediadas por inhiibicion de actividad syk, tales como cancer, trastornos alergicos o inflamatorios.

Info

Publication number
CL2011001361A1
CL2011001361A1 CL2011001361A CL2011001361A CL2011001361A1 CL 2011001361 A1 CL2011001361 A1 CL 2011001361A1 CL 2011001361 A CL2011001361 A CL 2011001361A CL 2011001361 A CL2011001361 A CL 2011001361A CL 2011001361 A1 CL2011001361 A1 CL 2011001361A1
Authority
CL
Chile
Prior art keywords
imidazo
cancer
treatment
pharmaceutical composition
amine
Prior art date
Application number
CL2011001361A
Other languages
English (en)
Inventor
Scott A Mitchell
Kevin S Blomgren Peter A Kropf Jeffrey E Lee Seung H Currie
Jianjun Stafford Douglas G Hu
Original Assignee
Gilead Connecticut Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42241250&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001361(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Connecticut Inc filed Critical Gilead Connecticut Inc
Publication of CL2011001361A1 publication Critical patent/CL2011001361A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos derivados de imidazo[1,2-a]pirazin amina, inhibidores de la actividad de la tirosina cinasa esplénica (syk); composición farmacéutica que los comprende; su uso para el tratamiento de enfermedades tales como cáncer, artritis reumatoide, rinitis alérgica, EPOC y una enfermedad inflamatoria. Además se menciona un método <em>in vitro </em>para determinar la presencia o ausencia de Syk en una muestra.
CL2011001361A 2008-12-08 2011-06-07 Compuestos derivados de n-(imidazo[1,2-a]pirazin-8-il)-1h-amina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades mediadas por inhiibicion de actividad syk, tales como cancer, trastornos alergicos o inflamatorios. CL2011001361A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12059008P 2008-12-08 2008-12-08
US14053508P 2008-12-23 2008-12-23
US24098309P 2009-09-09 2009-09-09

Publications (1)

Publication Number Publication Date
CL2011001361A1 true CL2011001361A1 (es) 2012-03-16

Family

ID=42241250

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001361A CL2011001361A1 (es) 2008-12-08 2011-06-07 Compuestos derivados de n-(imidazo[1,2-a]pirazin-8-il)-1h-amina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades mediadas por inhiibicion de actividad syk, tales como cancer, trastornos alergicos o inflamatorios.

Country Status (18)

Country Link
US (5) US8440667B2 (es)
EP (2) EP2373318B1 (es)
JP (2) JP5696052B2 (es)
KR (1) KR101743784B1 (es)
CN (2) CN104059073B (es)
AU (2) AU2009325133B2 (es)
BR (1) BRPI0922226A2 (es)
CA (1) CA2745871C (es)
CL (1) CL2011001361A1 (es)
CO (1) CO6390109A2 (es)
EA (1) EA021293B1 (es)
ES (1) ES2744541T3 (es)
IL (2) IL213405A0 (es)
MX (1) MX2011006094A (es)
NZ (1) NZ593460A (es)
PE (1) PE20120121A1 (es)
SG (2) SG171993A1 (es)
WO (1) WO2010068258A1 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587039A (en) 2008-02-13 2013-01-25 Gilead Connecticut Inc 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
ES2744541T3 (es) 2008-12-08 2020-02-25 Gilead Connecticut Inc Inhibidores de imidazopirazina Syk
SI2716157T1 (sl) 2008-12-08 2016-10-28 Gilead Connecticut, Inc., c/o Gilead Sciences, Inc. Imidazopirazinski Syk-inhibitorji
WO2011056895A1 (en) * 2009-11-03 2011-05-12 University Of Notre Dame Du Lac Ionic liquids comprising heteraromatic anions
MA33909B1 (fr) * 2009-12-23 2013-01-02 Takeda Pharmaceutical Pyrrolidinones accoles en tant d'inhibiteurs de syk
US9551710B2 (en) * 2010-02-09 2017-01-24 Drexel University Signaling molecule involved in ultraviolet damage to skin
KR101717809B1 (ko) * 2010-03-11 2017-03-17 질레드 코네티컷 인코포레이티드 이미다조피리딘 ｓｙｋ 억제제
TWI606049B (zh) 2011-04-21 2017-11-21 原真股份有限公司 新穎激酶抑制劑
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
EP2707357B1 (en) 2011-05-10 2017-01-18 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US9006444B2 (en) 2011-10-05 2015-04-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
WO2013052394A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
WO2013064445A1 (en) 2011-11-01 2013-05-10 F. Hoffmann-La Roche Ag Imidazopyridazine compounds
AU2012347350C1 (en) 2011-12-09 2017-01-19 Chiesi Farmaceutici S.P.A. Kinase inhibitors
MY167216A (en) 2011-12-09 2018-08-14 Chiesi Farm Spa Kinase inhibitors
KR20140108594A (ko) 2012-01-10 2014-09-11 에프. 호프만-라 로슈 아게 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도
US20130338142A1 (en) * 2012-06-14 2013-12-19 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
WO2013192128A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
US9242984B2 (en) 2012-06-20 2016-01-26 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as Syk inhibitors
WO2013192088A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9376418B2 (en) 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
US9353066B2 (en) 2012-08-20 2016-05-31 Merck Sharp & Dohme Corp. Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors
EP2900243A4 (en) 2012-09-27 2016-04-13 Portola Pharm Inc BICYCLIC OXA LACTAM KINASE HEMMER
WO2014048065A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
US9637491B2 (en) 2012-10-19 2017-05-02 Origenis Gmbh Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
RS58023B2 (sr) 2012-11-01 2021-12-31 Infinity Pharmaceuticals Inc Lečenje kancera korišćenjem modulatora izoformi pi3 kinaza
US9624210B2 (en) 2012-12-12 2017-04-18 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
US9598405B2 (en) 2012-12-21 2017-03-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014176216A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
WO2014176210A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
AU2014273946B2 (en) 2013-05-30 2020-03-12 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
BR112015029970A2 (pt) 2013-06-06 2017-07-25 Chiesi Farm Spa inibidores de cinase
TW201601728A (zh) 2013-07-30 2016-01-16 吉李德康乃狄克公司 脾酪胺酸激酶（ＳｙＫ）抑制劑之調合物
AU2014296308C1 (en) 2013-07-30 2018-09-13 Kronos Bio, Inc. Polymorph of Syk inhibitors
MX2016001427A (es) 2013-07-31 2016-08-03 Gilead Sciences Inc Inhibidores de syk.
WO2015048765A1 (en) 2013-09-30 2015-04-02 University Of Notre Dame Du Lac Compounds, complexes, compositions, methods and systems for heating and cooling
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6466924B2 (ja) 2013-10-04 2019-02-06 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10086331B2 (en) 2013-11-05 2018-10-02 University Of Notre Dame Du Lac Carbon dioxide capture using phase change ionic liquids
MX2016007311A (es) 2013-12-04 2016-09-07 Gilead Sciences Inc Metodos para tratar canceres.
WO2015094997A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095445A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095444A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
WO2015138273A1 (en) 2014-03-13 2015-09-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
BR112016028641A2 (pt) 2014-07-14 2017-08-22 Gilead Sciences Inc ?método para tratar câncer?
TW201617074A (zh) 2014-07-14 2016-05-16 吉李德科學股份有限公司 Ｓｙｋ（脾酪胺酸激酶）抑制劑
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016197987A1 (zh) * 2015-06-12 2016-12-15 杭州英创医药科技有限公司 作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物
CA2998250A1 (en) * 2015-09-11 2017-03-16 Boehringer Ingelheim International Gmbh Pyrazolyl-substituted heteroaryls and their use as medicaments
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
WO2018053190A1 (en) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Syk inhibitors
CN110099909B (zh) * 2016-12-12 2021-11-19 杭州英创医药科技有限公司 作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
US11058688B2 (en) * 2018-03-29 2021-07-13 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
EP3927708A1 (en) 2019-02-22 2021-12-29 Kronos Bio, Inc. Solid forms of condensed pyrazines as syk inhibitors
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2024110342A1 (en) 2022-11-23 2024-05-30 Koninklijke Philips N.V. Controlling a tactile breathing guidance device

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337609A (en) 1980-09-17 1982-07-06 Pitney Bowes Inc. Envelope stuffing apparatus
FR2607813B1 (fr) 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
DE4327027A1 (de) * 1993-02-15 1994-08-18 Bayer Ag Imidazoazine
DE4337609A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE4337611A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE4337656C2 (de) 1993-11-04 1996-01-18 Audi Ag Insassenschutzvorrichtung für Kraftfahrzeuge
FR2711993B1 (fr) 1993-11-05 1995-12-01 Rhone Poulenc Rorer Sa Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
DE69535592T2 (de) 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
FR2723373B1 (fr) 1994-08-02 1996-09-13 Rhone Poulenc Rorer Sa Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent
JPH11505524A (ja) 1995-05-01 1999-05-21 藤沢薬品工業株式会社 イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6249495B1 (en) 1997-02-27 2001-06-19 Matsushita Electric Industrial Co., Ltd. Stepping motor control method and disk drive apparatus
SE9704404D0 (sv) 1997-11-28 1997-11-28 Astra Ab New compounds
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6953413B2 (en) 2000-06-19 2005-10-11 Tay Armin S Axial position changing transmission mechanism
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
US20030089434A1 (en) 2000-11-20 2003-05-15 Flynn Thomas M. Method and apparatus for the preparation and usage of a cryogenic propellant or explosive system
DK174233B1 (da) 2000-12-27 2002-10-07 Dss Danish Separation Systems Sanitært spiralfilteranlæg
EP1363702A4 (en) 2001-01-30 2007-08-22 Cytopia Pty Ltd PROCESS FOR INHIBITING KINASES
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US7230941B2 (en) 2001-04-26 2007-06-12 Qualcomm Incorporated Preamble channel decoding
FR2824092B1 (fr) 2001-04-30 2004-04-09 Camille Jim Riviere Ensemble d'elements de construction
US7003125B2 (en) 2001-09-12 2006-02-21 Seung-Hwan Yi Micromachined piezoelectric microspeaker and fabricating method thereof
EP1308716A1 (en) * 2001-10-03 2003-05-07 Avantium International B.V. Method for performing a transmission diffraction analysis
WO2003070732A1 (en) 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
KR20050008691A (ko) * 2002-04-19 2005-01-21 셀룰러 지노믹스 아이엔씨 이미다조[1,2-ａ]피라진-8-일 아민, 그의 제조방법 및사용방법
US20040072081A1 (en) 2002-05-14 2004-04-15 Coleman Thomas P. Methods for etching photolithographic reticles
JP2004053714A (ja) 2002-07-17 2004-02-19 Fuji Xerox Co Ltd 画像定着装置及び画像定着方法
US20040026867A1 (en) 2002-08-09 2004-02-12 Adams David J. Bearing seal
US6761361B2 (en) 2002-08-09 2004-07-13 Credo Technology Corporation Drill and drive apparatus with improved tool holder
WO2004022562A1 (en) * 2002-09-09 2004-03-18 Cellular Genomics, Inc. 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
ATE378336T1 (de) 2002-09-19 2007-11-15 Schering Corp Imidazopyridine als hemmstoffe cyclin abhängiger kinasen
DE60317353T2 (de) 2002-09-23 2008-08-28 Schering Corp. Imidazopyrazine als cdk-inhibitoren
EP1542693A1 (en) * 2002-09-23 2005-06-22 Shering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
JP4056346B2 (ja) 2002-09-30 2008-03-05 三洋電機株式会社 非水電解質二次電池
KR101301653B1 (ko) 2002-10-29 2013-08-30 트랜세이브, 인코포레이티드 항감염제의 지속적인 방출
US7160885B2 (en) * 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
AR043002A1 (es) 2003-02-18 2005-07-13 Altana Pharma Ag Imidazopirazinas 6-substituidos
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7456393B2 (en) 2003-04-10 2008-11-25 Ge Homeland Protection, Inc. Device for testing surfaces of articles for traces of explosives and/or drugs
US7405295B2 (en) * 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US20060183746A1 (en) * 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) * 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US20050009632A1 (en) * 2003-07-08 2005-01-13 Karsten Manufacturing Corporation Iron type golf club head with low profile tuning port
WO2005019220A2 (en) 2003-08-11 2005-03-03 Cellular Genomics Inc. Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7236749B2 (en) 2003-10-15 2007-06-26 Honeywell International Inc. Stuck microphone deselection system and method
WO2005047290A2 (en) * 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
WO2005085252A1 (en) 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
JP2006099930A (ja) 2004-09-01 2006-04-13 Tdk Corp 情報記録媒体、記録再生装置およびスタンパー
US8145601B2 (en) 2004-09-09 2012-03-27 Microsoft Corporation Method, system, and apparatus for providing resilient data transfer in a data protection system
EP1812439B2 (en) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN101124227A (zh) 2004-11-10 2008-02-13 Cgi制药有限公司 可用作激酶活性调节剂的咪唑并[1,2-a]吡嗪-8-基胺
NZ555681A (en) 2004-11-10 2009-08-28 Cgi Pharmaceuticals Inc Imidazo[1, 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
JP4883959B2 (ja) 2005-08-17 2012-02-22 Ｎｔｎ株式会社 回転検出装置および回転検出装置付き軸受
GB0520838D0 (en) * 2005-10-13 2005-11-23 Glaxo Group Ltd Novel compounds
AR056785A1 (es) * 2005-11-10 2007-10-24 Schering Corp COMPUESTOS DE IMIDAZO[1,2-A]PIRAZINAS, uTILES COMO INHIBIDORES, REGULADORES O MODULADORES DE PROTEINQUINASAS
CA2628534A1 (en) 2005-11-10 2007-05-18 Schering Corporation Methods for inhibiting protein kinases
JP4837378B2 (ja) 2006-01-04 2011-12-14 株式会社日立製作所 データの改竄を防止する記憶装置
US7446352B2 (en) 2006-03-09 2008-11-04 Tela Innovations, Inc. Dynamic array architecture
DE102006032495A1 (de) 2006-07-13 2008-02-07 Nokia Siemens Networks Gmbh & Co.Kg Verfahren und Vorrichtung zur Vermeidung von Interferenzen in einem zellulären Funkkommunikationssystem
US20080025821A1 (en) 2006-07-25 2008-01-31 Applied Materials, Inc. Octagon transfer chamber
CN103641829A (zh) 2006-08-30 2014-03-19 塞尔佐姆有限公司 作为激酶抑制剂的***衍生物
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
EP2099798A1 (en) 2006-12-01 2009-09-16 Galapagos N.V. Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
US7657023B2 (en) 2007-06-08 2010-02-02 At&T Intellectual Property I, L.P. Splitter wall plates for digital subscriber line (DSL) communication systems and methods to use the same
JP5643105B2 (ja) 2007-12-14 2014-12-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規イミダゾ［１，２−ａ］ピリジン及びイミダゾ［１，２−ｂ］ピリダジン誘導体
NZ587039A (en) 2008-02-13 2013-01-25 Gilead Connecticut Inc 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof
WO2009155388A1 (en) 2008-06-20 2009-12-23 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
CA2726460C (en) 2008-07-15 2017-02-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
MX2010013190A (es) * 2008-07-18 2010-12-20 Hoffmann La Roche Fenilimidazopirazinas novedosas.
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基***并吡啶，其組合物及使用其之治療方法
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
ES2744541T3 (es) * 2008-12-08 2020-02-25 Gilead Connecticut Inc Inhibidores de imidazopirazina Syk
SI2716157T1 (sl) 2008-12-08 2016-10-28 Gilead Connecticut, Inc., c/o Gilead Sciences, Inc. Imidazopirazinski Syk-inhibitorji
US20110112995A1 (en) 2009-10-28 2011-05-12 Industrial Technology Research Institute Systems and methods for organizing collective social intelligence information using an organic object data model
KR101717809B1 (ko) 2010-03-11 2017-03-17 질레드 코네티컷 인코포레이티드 이미다조피리딘 ｓｙｋ 억제제
US20140148430A1 (en) 2012-11-26 2014-05-29 Gilead Connecticut, Inc. Imidazopyridines syk inhibitors
TW201601728A (zh) 2013-07-30 2016-01-16 吉李德康乃狄克公司 脾酪胺酸激酶（ＳｙＫ）抑制劑之調合物
AU2014296308C1 (en) 2013-07-30 2018-09-13 Kronos Bio, Inc. Polymorph of Syk inhibitors
MX2016001427A (es) 2013-07-31 2016-08-03 Gilead Sciences Inc Inhibidores de syk.
MX2016007311A (es) 2013-12-04 2016-09-07 Gilead Sciences Inc Metodos para tratar canceres.
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
BR112016028641A2 (pt) 2014-07-14 2017-08-22 Gilead Sciences Inc ?método para tratar câncer?
TW201617074A (zh) 2014-07-14 2016-05-16 吉李德科學股份有限公司 Ｓｙｋ（脾酪胺酸激酶）抑制劑
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
BR112017022323A2 (pt) 2015-04-21 2018-07-03 Gilead Sciences, Inc. método para tratar doença do enxerto contra hospedeiro, uso de um composto, e, kit.
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
WO2018053190A1 (en) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Syk inhibitors

Also Published As

Publication number Publication date
US8440667B2 (en) 2013-05-14
CN104059073A (zh) 2014-09-24
IL213405A0 (en) 2011-07-31
EP3552607A3 (en) 2020-01-15
EA021293B1 (ru) 2015-05-29
US20150266902A1 (en) 2015-09-24
EP2373318A4 (en) 2012-05-30
EP3552607A2 (en) 2019-10-16
US9567348B2 (en) 2017-02-14
SG10201707798SA (en) 2017-10-30
AU2016202807B2 (en) 2017-10-12
PE20120121A1 (es) 2012-02-20
US10093684B2 (en) 2018-10-09
EP2373318A1 (en) 2011-10-12
ES2744541T3 (es) 2020-02-25
JP5696052B2 (ja) 2015-04-08
WO2010068258A1 (en) 2010-06-17
SG171993A1 (en) 2011-07-28
US8962835B2 (en) 2015-02-24
AU2009325133A1 (en) 2011-06-30
CN104059073B (zh) 2017-04-12
US20100152159A1 (en) 2010-06-17
US8796270B2 (en) 2014-08-05
CN102307581A (zh) 2012-01-04
EA201190043A1 (ru) 2012-02-28
US20130231330A1 (en) 2013-09-05
NZ593460A (en) 2013-11-29
US20130310363A1 (en) 2013-11-21
JP2012510998A (ja) 2012-05-17
BRPI0922226A2 (pt) 2015-12-29
CN102307581B (zh) 2016-08-17
EP2373318B1 (en) 2019-06-05
MX2011006094A (es) 2011-11-29
CA2745871A1 (en) 2010-06-17
KR101743784B1 (ko) 2017-06-05
JP2014148546A (ja) 2014-08-21
AU2016202807A1 (en) 2016-05-26
CA2745871C (en) 2018-02-20
CO6390109A2 (es) 2012-02-29
US20170121350A1 (en) 2017-05-04
KR20110098794A (ko) 2011-09-01
IL242955A (en) 2017-09-28
AU2009325133B2 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
CL2011001361A1 (es) Compuestos derivados de n-(imidazo[1,2-a]pirazin-8-il)-1h-amina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades mediadas por inhiibicion de actividad syk, tales como cancer, trastornos alergicos o inflamatorios.
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
CR20130617A (es) Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias
CO6602133A2 (es) Derivados de i,idazo(1,2-a)pirazina y su uso para la prevencion o tratamiento de trastornos y enfermedades neurologicas, siquiatricas y metabolicas
PA8675701A1 (es) Nuevos derivados del fluoreno, composiciones que los contienen y su utilización
NZ602362A (en) Imidazopyridines syk inhibitors
ECSP11011011A (es) Derivados de acido 1-amino-2-ciclobutiletilborónico
AR077144A1 (es) Derivado de fenilimidazol como inhibidor de la enzima pde10a, composiciones farmaceuticas y uso de los mismos en el tratamiento de trastornos neurodegenerativos y psiquiatricos
EA201001242A1 (ru) ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
CL2013002063A1 (es) Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune.
ME01269B (me) Jedinjenja pirolo (2,3-d) pirimidina
ECSP11011181A (es) Compuestos orgánicos
ECSP11011182A (es) Compuestos orgánicos
CL2011001360A1 (es) Compuestos derivados de imidazol[1,2-a]pirazin-8-amina, inhibidores de tirosina quinasa esplenica; composicion farmaceutica que comprende un compuesto; uso de los compuestos en la preparacion de medicamentos para el tratamiento de trastornos alergicos, enfermedades autoinmunes y enfermedades inflamatorias; y metodo in vitro.
CL2010001641A1 (es) Compuestos derivados de heterociclos biciclicos sustituidos; composicion farmaceutica; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas e inflamatorias tales como cancer y artritis reumatoide entre otras.
CL2012002270A1 (es) Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer.
CL2008003577A1 (es) Compuestos derivados de imidazo[1,5-a] pirido[3,2-e]pirazina, 2, 6, 7, 9 tetrasustituidos; inhibidores de fosfodiesterasa 10; procedimiento de preparación; composición farmacéutica que comprende a dichos compuestos; y su uso para tratar enfermedades relacionadas con el sistema nervioso central, obesidad y trastornos del metabolismo.
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
UY33503A (es) Imidazo [1,2-a]pirimidinas y piridinas sustituidas
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
ECSP12012218A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
SV2007002397A (es) Aminopiridinas como inhibidores de b-secretasa ref. am101663
CO6781467A2 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
CL2012001027A1 (es) Compuestos derivados de 7-(fenilamina)-5-oxo-1,2,3,5-tetrahidro-imidazo[1,2-a]piridina, 7-(fenilamina)5-oxo-2,3-dihidro-5h-tiazolo[3,2-a]piridina, 7-(fenulaminas)-5-oxo-2,3-dihidro-2hoxazolo[3,2-a]piridina: composicion farmaceutica; utiles en el tratamiento de enfermedades, trastornos o sindrome asociado con la inhibicion mek.